Prior Authorization Policy
|
|
- Roland Pope
- 8 years ago
- Views:
Transcription
1 Prior Authorization Policy Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin tablet), Ribapak (ribavirin tablet), ribavirin (generic capsule and tablet) Pharmacy Benefit Commercial HMO / PPO / CDHP Setting Self-administered: Oral Medical Benefit Approval period Initial approval: 8 weeks Continued approval: up to 48 weeks CPT/HCPCS code J8499, J7699 Available through Paramount s specialty pharmacy network. Description of Medication Ribavirin is a synthetic nucleoside analog (purine analog) with antiviral activity. The mechanism by which the combination of ribavirin and an interferon product exerts its effects against the hepatitis C virus has not been fully established. 1-3, 12 FDA-APPROVED INDICATIONS Rebetol Rebetol is indicated in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age and older with compensated liver disease. Copegus Copegus is indicated in combination with Pegasys for the treatment of adults with CHC virus infection who have compensated liver disease and have not been previously treated with alpha interferon. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). Moderiba Moderiba is indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa- 2a in adults with compensated liver disease not previously treated with interferon alpha, and in CHC patients coinfected with HIV. Ribasphere Ribasphere is indicated in combination with peginterferon alfa-2a for the treatment of adults with CHC virus infection who have compensated liver disease and have not been previously treated with alpha interferon. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A). Web document
2 Recommended authorization criteria For all patients with hepatitis C infection, ribavirin must be prescribed by, or in consultation with, a gastroenterologist, specializing in hepatology, an infectious disease physician, or a transplant physician. CRITERIA FOR APPROVAL 1. Does the patient have any of the following contraindications to ribavirin therapy? Hemoglobin <8.5 g/dl Hemoglobinopathy Poorly controlled or deteriorating cardiac disease Patient or the partner of the patient is pregnant Unwilling to use adequate contraception (self or partner) The patient is currently receiving or will be receiving Videx (didanosine) 2. Does the patient meet one of the following: Has a creatinine clearance (CrCl) 50 ml/min OR Has CrCl <50 ml/min and will use reduced dose of ribavirin and interferon with careful monitoring by a specialist 3. Prior to initiating therapy, did the patient have a diagnosis of chronic hepatitis C virus (HCV) infection as confirmed by detectable viral load in the serum? 4. Does the patient have genotype 2 or 3 infection? [If no, skip to question 6.] 5. Has the patient received 24 weeks of therapy as part of this treatment course? [ further questions.] 6. Is the patient being prescribed ribavirin as part of a three-drug treatment regimen that includes peginterferon alfa (e.g. Pegasys, PegIntron) and Victrelis? [If yes, skip to question 17.] 7. Is the patient being prescribed ribavirin as part of a three-drug regimen that includes peginterferon alfa (e.g. Pegasys, PegIntron) and Incivek? [If yes, skip to question 26.] 8. Is the patient being prescribed ribavirin as part of a two-drug treatment regimen that includes non-pegylated interferon alfa (e.g. Intron)? [If no, skip to question 10.] 9. Has the patient had a documented adverse reaction (ADR) or is the patient at higher risk for an ADR with pegylated interferon alfa (e.g. Pegasys, PegIntron)? [If yes, skip to question 16.] 10. Is the patient being prescribed ribavirin as part of a two-drug treatment regimen that includes pegylated interferon alfa (e.g. Pegasys, PegIntron)? [If no, skip to question 16.] 11. Is the patient Genotype 1 or Genotype 4? 12. Has the patient received 12 weeks of therapy as part of this treatment course? 13. Did the patient have undetectable HCV RNA at week 12 of treatment? [If yes, skip to question 16.] 14. Has the patient received 24 weeks of therapy as part of this treatment course? 15. Did the patient have undetectable HCV RNA after 24 weeks of treatment? 16. Has the patient received 48 weeks of therapy as part of this treatment course? [ further questions.] 17. Does the patient meet all of the following criteria for approval?
3 Has genotype 1 infection HCV RNA will be assessed at weeks 4, 8, 12, and 24 of treatment Has/will receive 4 weeks of PEG-IFN and ribavirin prior to starting Victrelis 18. Has the patient received 12 weeks of PEG-IFN and ribavirin and 8 weeks Victrelis? 19. Did the patient have HCV RNA 100 IU/mL at week 12 of treatment? 20. Has the patient received 24 weeks of PEG-IFN and ribavirin and 20 weeks Victrelis? 21. Did the patient have undetectable HCV RNA at week 24 of treatment? 22. Does the patient meet one of the following? Patient has cirrhosis OR Patient was poorly IFN responsive (<1.0-log 10 HCV-RNA decline in viral load) at week 4 of treatment 23. Is the request for retreatment of chronic HCV infection? [If no, skip to question 25.] 24. With prior therapy, did the patient have <2-log 10 drop in HCV-RNA after 12 weeks of treatment (i.e., null response)? 25. Did the patient have undetectable HCV RNA at week 8 of treatment? [ further questions.] 26. Does the patient meet both of the following? Has genotype 1 infection HCV RNA will be assessed at weeks 4, 12, and 24 of treatment 27. Has the patient received 4 weeks of ribavirin in combination with Incivek and PEG-IFN? 28. Did the patient have HCV RNA >1,000 IU/mL at week 4 of treatment? 29. Has the patient received 12 weeks of ribavirin in combination with Incivek and PEG-IFN? 30. Did the patient have HCV RNA >1,000 IU/mL at week 12 of treatment? 31. Is the patient treatment-naïve or prior relapser to HCV therapy? [If no, skip to question 34.] 32. Does the patient have cirrhosis? [If yes, skip to question 34.] 33. Did the patient have undetectable HCV RNA at weeks 4 and 12 of treatment? 34. Has the patient received 24 weeks of ribavirin in combination with Incivek and peginterferon alfa? 35. Did the patient have undetectable HCV RNA at week 24 of treatment? Special Populations - Retreatment Due to nresponse or Relapse Retreatment is considered for patients who did not achieve SVR with their prior course of therapy. 8 For nonresponders and relapsers to IFN monotherapy, higher SVR can be achieved with retreatment with IFN and ribavirin combination therapy. 8,10 The addition of protease inhibitor to PEG-IFN and ribavirin increases the rates of SVR and shortens the duration of treatment for genotype 1 nonresponders and relapsers. 12
4 Exclusions (Limitations) Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria or under the following circumstances. Criteria will be updated as new published data are available. Oral formulations 13 : Hypersensitivity to ribavirin or any component of the formulation; women who are pregnant or may become pregnant; males whose female partners are pregnant; patients with hemoglobinopathies (eg, thalassemia major, sickle cell anemia); patients with autoimmune hepatitis; concomitant use with didanosine. Ribasphere capsules and Rebetol capsules/solution 13 : Additional contraindications: Patients with a CrCl <50 ml/minute. Oral combination therapy with alfa interferons 13 : Autoimmune hepatitis, hepatic decompensation (Child-Pugh score >6; class B and C) in cirrhotic chronic hepatitis C monoinfected patients prior to treatment, hepatic decompensation (Child-Pugh score 6) in cirrhotic chronic hepatitis C patients coinfected with HIV prior to treatment. Also refer to individual monographs for Interferon Alfa-2b (Intron A), Peginterferon Alfa-2b, and Peginterferon Alfa-2a (Pegasys) for additional contraindication information. Indications lacking evidence to support medical necessity as defined below 14 : 1) The drug is not FDA approved for the indication prescribed; PLUS a. Standard medical reference compendia state that the drug is ineffective or unsafe for the off-label indication requested; OR b. The medical compendia is silent on the topic for the indication requested; AND i. One or more medical articles exist that conclude the drug is unsafe and/or ineffective; OR ii. iii. One or more medical articles concludes that safety and efficacy cannot be determined; OR Less than two articles in medical literature show safety and effectiveness for the indication prescribed *Major medical articles must meet uniform requirements for manuscripts to biomedical journals, be published in major peer-reviewed professional medical journals, be sound in methodology, sound statistically, and free from overt bias. Endorsed: 07/30/14 Approved: 08/12/14 Revised: Reviewed: Criteria adapted from CVS/Caremark Prior Authorization Policy MDC 558-A. Effective 04/2014 REFERENCES 1. Rebetol [package insert]. Kenilworth, NJ: Schering Corporation; October Copegus [package insert]. Nutley, NJ: Roche Laboratories Inc.; August Ribasphere [package insert]. Cranberry Township, PA: Three Rivers Pharmaceuticals, LLC.; February PegIntron [package insert]. Kenilworth, NJ: Schering-Plough Corporation; August Victrelis [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; February Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals Inc.; April Dienstag JL, McHutchinson JG. American Gastroenterological Association Medical Position on the Management of Hepatitis C. Gastroenterology. 2006;130(1): Thompson A, Patel K, Tillman H, et al. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol. 2009;50(1): Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4): Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4): Singal AG, Waljee AK, Shiffman M, et al. Meta-analysis: re-treatment of genotype 1 hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther. 2010;32: Moderiba [package insert]. rth Chicago, IL: AbbVie, Inc.; vember Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online, Hudson, Ohio: Lexi-Comp, Inc.; July 21, 2014
5 14. Ohio Revised Code Title [17] XVII Corporations Partnerships; Chapter 1751 Health Insuring Corporation law; Prescription Drugs accessed at on 07/22/14.
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Pegasys and non-preferred Hepatitis C Agents must
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationHEPATITIS C TREATMENT GUIDELINES
HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationPURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.
COVENTRY Health Care Guidelines for Hepatitis B Therapy SUBJECT: Chronic Hepatitis B Therapy: a. Interferons - Intron A (interferon alfa-2b) and Pegasys (peginterferon alfa-2a) b. Nucleoside analogues
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationLedipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C
Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
More informationHepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form
Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form For assistance, please call 1-855-552-6028 or fax completed form to 570-271-5610. Medical documentation may be requested. This
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationMonitoring of Treatment of viral hepatitis C
Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred
More informationRequest for Prior Authorization HEPATITIS C TREATMENTS
IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax
More informationIntroduction. Background
INFORMATION DRIVES SOUND ANALYSIS, INSIGHT PHARMACY BENEFIT ADVISORY Introduction According to the Centers for Disease Control and Prevention (CDC), the rate of new hepatitis C virus (HCV) infections in
More informationHepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary
Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx
More informationSovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
More informationHepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011
Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call March 16, 2011 Case Presentations Kansas City Free Health Clinic Carilion Clinic Didactic Session Challenges in Determining HCV Treatment
More informationTreating Chronic Hepatitis C. A Review of the Research for Adults
Treating Chronic Hepatitis C A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have chronic hepatitis C.
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationScottish Medicines Consortium
Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10
More informationA Proposal for Managing the Harvoni Wave June 22, 2015
A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects
More informationPlease see full Prescribing Information, including boxed warning and Medication Guide, on pages 15-48. Your Treatment.
Please see full Prescribing Information, including boxed warning and Medication Guide, on pages 15-48. Your Treatment Our Commitment CONTENTS INTRODUCTION ABOUT RIBASPHERE RIBAPAK DOSING GETTING STARTED
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationNjeri Thande. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume X 2005-2006. A. Study Purpose and Rationale
Etanercept as an adjuvant to pegylated interferon alpha and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a randomized, double-blind, placebocontrolled study Njeri Thande
More informationPreamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases A new section on Use and Interpretation of
More informationSCIENTIFIC DISCUSSION
London, 13 October 2005 Product name: PEGINTRON Procedure No. EMEA/H/C/280/II/54 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationREVIEW CLINICAL AND SYSTEMATIC REVIEWS
CLINICAL AND SYSTEMATIC S nature publishing group 1 Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center
More informationThe question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationVictrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD
Victrelis: hints for success Katarnya Gilbert Hepatology MSL MSD 1 Some Facts: BOC has no clinically significant activity against other HCV genotypes. Resistance with protease inhibitor monotherapy can
More informationHIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationProtease Inhibitors for Chronic Hepatitis C Infection: The New Kids on the Block, But do they have The Right Stuff for all patients?
Protease Inhibitors for Chronic Hepatitis C Infection: The New Kids on the Block, But do they have The Right Stuff for all patients? Lindsey M. Childs, PharmD, MPH PGY2 Infectious Diseases Pharmacy Resident
More informationAASLD PRACTICE GUIDELINE Diagnosis, Management, and Treatment of Hepatitis C
AASLD PRACTICE GUIDELINE Diagnosis, Management, and Treatment of Hepatitis C Doris B. Strader, 1 Teresa Wright, 2,3 David L. Thomas, 4 and Leonard B. Seeff 5,6 Preamble These recommendations provide a
More informationHepatitis C Antiviral Therapy
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Hepatitis C Antiviral Therapy Number 5.01.606 Effective Date
More informationCoinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
More informationHepatitis C Treatment: Tailoring Therapy To Maximize Response
PRINTER-FRIENDLY VERSION AT GASTROENDONEWS.COM Hepatitis C Treatment: Tailoring Therapy To Maximize Response PATRICK J. AMAR, MD Department of Gastroenterology and Hepatology Holy Cross Medical Group Fort
More informationTreatment of Hepatitis C in Patients with Renal Insufficiency
HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,
More informationFebruary 2016. page 1 / 9
February 2016 page 1 / 9 page 2 / 9 Alternative Medicines Corner Advising on this article: Nicole M. Maisch February 1, 2016 Melatonin supplementation may improve outcomes in children with atopic dermatitis
More informationViral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines
Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationCommissioning Policy for Hepatitis C Treatments
Commissioning Policy for Hepatitis C Treatments Reference No: EMSCGP012V1 Version: 1 Ratified by: East Midlands Specialised Commissioning Group Date ratified: 05/06/09 Name of originator/author: Andrew
More informationNHS GRAMPIAN. Community Pharmacy Supply Of Hepatitis C Treatments. Pharmaceutical Care Information Pack
NHS GRAMPIAN Community Pharmacy Supply Of Hepatitis C Treatments Pharmaceutical Care Information Pack NHS Grampian Hepatology Team April 2015 NHS GRAMPIAN Community Pharmacy Supply Of Hepatitis C Treatments
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationTreatment of Hepatitis C with Pegylated Interferon and Ribavirin, with or without Boceprevir or Telaprevir
of Hepatitis C with Pegylated Interferon and Ribavirin, with or without Boceprevir or Telaprevir Federal Bureau of Prisons Clinical Practice Guidelines May 2014 Clinical guidelines are made available to
More informationAASLD PRACTICE GUIDELINE
AASLD PRACTICE GUIDELINE An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases Marc G. Ghany, 1 David
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationHepatitis C Virus and HIV Co-infection 2015 Update. Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015
Hepatitis C Virus and HIV Co-infection 2015 Update Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015 1 Statement of Disclosure Presenter has no relevant financial
More informationSafety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
More informationNews Release. FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 (908) 740-1898
News Release FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 Investor Contact: Amy Klug (908) 740-1898 Merck Receives Approval of ZEPATIER (elbasvir/grazoprevir) in Canada for the Treatment
More informationHepatitis C Infection In Singapore
Hepatitis C Infection In Singapore Richard Guan MBBS, MRCP(UK), FAMS(Gastro), FRCP(Edin), FRCP(Lond) Gastroenterologist & Hepatologist, Mt Elizabeth Medical Centre, Singapore Summary of HCV treatment practice
More informationLA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
More informationHCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
More informationEfficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
More informationNEW APPROACHES TO THE MANAGEMENT OF HEPATITIS C IN HEMOPHILIA
TREATMENT OF HEMOPHILIA December 2012 No. 54 NEW APPROACHES TO THE MANAGEMENT OF HEPATITIS C IN HEMOPHILIA Fabien Zoulim François Bailly Hepatology Department Hospices Civils de Lyon, Université de Lyon
More informationPatients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Liver International ISSN 1478-3223 REVIEW ARTICLE Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Mitchell L. Shiffman 1 and Yves Benhamou 2 1 Liver Institute of Virginia, Bon Secours
More informationBoceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford Brass, Antoine
More informationHepatitis C Virus (HCV)
HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median
More informationThe Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection
The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection A Technology Assessment Final Report April 15, 2014 Completed by: Institute
More informationFor the management of chronic hepatitis C virus. Individualized Treatment Duration for Hepatitis C Genotype 1 Patients: A Randomized Controlled Trial
Individualized Treatment Duration for Hepatitis C Genotype 1 Patients: A Randomized Controlled Trial Alessandra Mangia, 1 Nicola Minerva, 2 Donato Bacca, 3 Raffaele Cozzolongo, 4 Giovanni L. Ricci, 5 Vito
More informationCurrent & New Hepatitis C Meds on the Horizon
Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated
More informationDisclosure. Pharmacy technician objectives. Pharmacist objectives. Epidemiology. Terminology 3/3/2015. Treatment of Hepatitis C
Disclosure Treatment of Hepatitis C Katerina Tagaras PGY-1 Resident Palmetto General Hospital I do not have a vested interest in or affiliation with any corporate organization offering financial support
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationHepatitis C Treatment Advocacy: Ireland. Brian O Mahony
Hepatitis C Treatment Advocacy: Ireland Brian O Mahony Haemophilia and Hepatitis C 775 people with Haemophilia in Ireland 252 people with Haemophilia infected with Hepatitis C before 1992 106 of these
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationHCV treatment today: pegylated interferons and ribavirin
HCV treatment today: pegylated interferons and ribavirin Other special patient populations Patients with cirrhosis Higher SVR rates are achieved in patients without cirrhosis Patients without bridging
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationdoi:10.1111/j.1365-2893.2009.01255.x
Journal of Viral Hepatitis, 2010, 17, 459 468 doi:10.1111/j.1365-2893.2009.01255.x Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients
More informationIndividualizing treatment duration in hepatitis C virus genotype 2/3-infected patients
Liver International ISSN 1478-3223 REVIEW ARTICLE Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients Alessandra Mangia Liver Unit, IRCCS Hospital Casa Sollievo della
More informationI. What s New and Updates/Changes (Last updated: February 17, 2015; last reviewed: February 17, 2015) Summary Table
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health Contents I. What
More informationAll hepatitis C medications are specialty products; dispensing is available only via BriovaRx specialty pharmacy.
Hepatitis C Medications Prior Authorization Criteria Harvoni (ledipasvir/sofosbuvir), Sovaldi (sofosbuvir), Olysio (simeprevir) #, pegylated interferon (Pegasys & Peg-Intron ), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationThe Pegylated Interferons: Treating Hepatitis C. Comparing Effectiveness, Safety, and Price
The Pegylated Interferons: Treating Hepatitis C Comparing Effectiveness, Safety, and Price Our Recommendations Pegylated interferons are used to treat hepatitis C virus infection, usually in combination
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationL hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015
L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015 Demographics Luis Rivero Pinelo MD LMCC, CCFP, FCFP, Fellow SRPC, CSPQ Shawville- Québec Aux États Unis, la prévalence est présente
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationDE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationTreatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011
CLINICAL GUIDELINES DANISH MEDICAL JOURNAL Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011 Peer Brehm Christensen, Mette Rye Clausen, Henrik
More informationVERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA FORM 8-K (Unscheduled Material Events) Filed 6/1/2005 For Period Ending 5/31/2005 Address 130 WAVERLY STREET CAMBRIDGE, Massachusetts 02139-4242 Telephone 616-577-6000 CIK
More information